ERBB2 and breast cancer: Determination of HER2 overexpression in BC tissue has a role in clinical decisions, as it is associated with an unfavourable prognosis, especially in patients with lymph node metastases3, with greater resistance to hormonal therapy and some chemotherapeutical agents4,5 and with increased sensitivity to other chemotherapy regimens6,7.